Literature DB >> 14697639

Molecular cytogenetic characterization of rhabdomyosarcoma cell lines.

Sandra Rodriguez-Perales1, Angel Martínez-Ramírez, Sara Alvarez de Andrés, Laura Valle, Miguel Urioste, Javier Benítez, Juan C Cigudosa.   

Abstract

Alveolar rhabdomyosarcomas (ARMS) are soft-tissue tumors that are genetically characterized by the presence of reciprocal translocations that generate the fusion gene PAX3-FOXO1A or PAX7-FOXO1A. For the study of the biologic consequences of such rearrangements, several cell lines have been generated. However, established cell lines accumulate chromosome and genetic aberrations that make it difficult to draw significant conclusions. We have applied a set of techniques that includes spectral karyotyping, fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and microarray CGH, to the most commonly used cell lines carrying the two fusion genes that are present in ARMS. We have identified the bacterial artificial chromosomes that cover the breakpoints at genes PAX3, PAX7, and FOXO1A, which can be used as FISH probes for the translocations. The RH30 cell line, positive for the PAX3-FOXO1A fusion gene, was found to be highly complex: wide range of chromosome number, more than 50 chromosome rearrangements, amplification of the hybrid gene, 24 DNA changes detected by conventional CGH, and 21 gene copy changes detected by microarray CGH (including several high-level amplifications). RMZ-RC2 cell line, positive for the PAX7-FOXO1A, was in the near-tetraploid range with only nonclonal structural rearrangements, amplification of the hybrid gene, 24 DNA changes by CGH, and 8 gene copy changes, confirming the previously reported high-level amplification of MYCN.

Entities:  

Mesh:

Year:  2004        PMID: 14697639     DOI: 10.1016/s0165-4608(03)00216-4

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

2.  Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.

Authors:  Myriam Goldstein; Isaac Meller; Josephine Issakov; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

Review 3.  Molecular cytogenetics in translational oncology: when chromosomes meet genomics.

Authors:  M J Calasanz; J C Cigudosa
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

4.  Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog.

Authors:  Dana C Baiu; Ian R Marsh; Alexander E Boruch; Ankita Shahi; Saswati Bhattacharya; Justin J Jeffery; Qianqian Zhao; Lance T Hall; Jamey P Weichert; Bryan P Bednarz; Mario Otto
Journal:  J Nucl Med       Date:  2017-07-26       Impact factor: 10.057

5.  Chromosomal and genetic imbalances in Chinese patients with rhabdomyosarcoma detected by high-resolution array comparative genomic hybridization.

Authors:  Chunxia Liu; Dongliang Li; Jianming Hu; Jinfang Jiang; Wei Zhang; Yunzhao Chen; Xiaobin Cui; Yan Qi; Hong Zou; Wenjie Zhang; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

6.  Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival.

Authors:  Bryan C Barnhart; Jennifer C Lam; Regina M Young; Peter J Houghton; Brian Keith; M Celeste Simon
Journal:  Cancer Biol Ther       Date:  2008-09-11       Impact factor: 4.742

7.  Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.

Authors:  Ashley R P Hinson; Rosanne Jones; Lisa E S Crose; Brian C Belyea; Frederic G Barr; Corinne M Linardic
Journal:  Front Oncol       Date:  2013-07-17       Impact factor: 6.244

8.  EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.

Authors:  Matthew E Randolph; Megan M Cleary; Zia Bajwa; Matthew N Svalina; Michael C Young; Atiya Mansoor; Pali Kaur; Carol J Bult; Martin W Goros; Joel E Michalek; Sunny Xiang; James Keck; Valery Krasnoperov; Parkash Gill; Charles Keller
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

9.  Novel Roles for Staufen1 in Embryonal and Alveolar Rhabdomyosarcoma via c-myc-dependent and -independent events.

Authors:  Tara E Crawford Parks; Kristen A Marcellus; Jonathan Langill; Aymeric Ravel-Chapuis; Jean Michaud; Kyle N Cowan; Jocelyn Côté; Bernard J Jasmin
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

10.  Analysis of molecular cytogenetic alteration in rhabdomyosarcoma by array comparative genomic hybridization.

Authors:  Chunxia Liu; Dongliang Li; Jinfang Jiang; Jianming Hu; Wei Zhang; Yunzhao Chen; Xiaobin Cui; Yan Qi; Hong Zou; WenJie Zhang; Feng Li
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.